Category: Prostate Cancer

In recent years, there’s been a huge shift in understanding the difference between insignificant and significant prostate cancer (PCa). Over 15 years ago, Albertsen, et al. (2005) established that clinically insignificant PCa could be defined as cancer that “will not affect the patient during the natural course of his lifetime. The indolent course of localised keep reading

“Limited attention has been given to the psychological impact of primary treatments in patients with prostate cancer.” We want to update our original post (below) about dementia/cognitive decline in relation to radical prostatectomy, by broadening it out to... keep reading

It was bad news then, and five years down the road it’s still bad news. According to Barnett, et al. (2021), “Of the risks associated with RT, the development of a secondary malignancy is of most concern for the patient and physician.” The blog we posted below presented a 2016 paper on prostate cancer radiation therapy as a catalyst for... keep reading

UPDATE: 10/26/2021 Originally published 7/7/2018 Dr. Snuffy Myers may be the world’s champion at durable remission of the prostate cancer (PCa). As a now-retired oncologist and survivor of the disease, he continues to lead, inspire and inform PCa patients. This update emphasizes Key Lifestyle Factor #4 in the original blog, Healthy Diet, based on a keep reading

Over the years, I have spoken with many patients about the idea of doctors being 100% open with regard to their treatment results. I came across a large-scaled Swedish study on prostatectomy side effects, and it’s as transparent as it gets. keep reading

Everyone has heard the term “chemotherapy” and it conjures up scary, negative images. On the other hand, have you heard the term “chemoprevention”? The National Cancer Institute defines chemoprevention as “the use of pharmacologic or natural agents that inhibit the development of invasive cancer... keep reading

Just under six months ago, the FDA approved the first radiopharmaceutical, Gallium-68 PSMA-11, for prostate cancer (PCa) detection by PET-CT scans. Approval meant that this injectable isotope had achieved special status as “a first”. The FDA granted its approval for two purposes: (a) Suspicion of PCa recurrence after treatment, and (b)Suspicion of metastasis (spread) at keep reading

Beyond doubt, PSA screening for prostate cancer (PCa) has saved hundreds of thousands of lives since the blood test was introduced in the mid-1990s. However, the classical screening strategy involved a pathway from a suspiciously high or rising PSA directly to... keep reading

In 2014, the International Society of Urological Pathology released a proposed new prostate cancer grading system, called the Grade Groups (GG). Our initial post explains some of the reasoning behind simplifying the traditional Gleason scoring system into a more understandable 5-point aggression scale... keep reading

In 2009, Gat et al.[iv] published a paper that should have made a much bigger splash than it did. They accounted for the origin of two major prostate problems with one simple explanation: blood “backing up” into the prostate from the testicles. keep reading